Company Description
Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin care, oral care, wound care, and women's health fields, nutritional and over-the-counter pharmaceutical products. The company's Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, thrombosis, vaccines, and infectious diseases. Its Medical Devices and Diagnostics segment offers electrophysiology and circulatory disease management products; orthopaedic joint reconstruction, spinal care, neurological, and sports medicine products; surgical care, aesthetics, and women's health products. Johnson & Johnson is based in New Brunswick, New Jersey.
Financials, Fundamental Metrics & Ratios
| Revenue (Most Recent Fiscal Year) |
$82.06B |
| Net Income (Most Recent Fiscal Year) |
$15.12B |
| PE Ratio (Current Year Earnings Estimate) |
18.04 |
| PE Ratio (Trailing 12 Months) |
19.91 |
| PEG Ratio (Long Term Growth Estimate) |
3.11 |
| Price to Sales Ratio (Trailing 12 Months) |
5.22 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) |
6.55 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) |
13.91 |
| Pre-Tax Margin (Trailing 12 Months) |
23.58% |
| Net Margin (Trailing 12 Months) |
21.01% |
| Return on Equity (Trailing 12 Months) |
34.64% |
| Return on Assets (Trailing 12 Months) |
13.40% |
| Current Ratio (Most Recent Fiscal Quarter) |
1.48 |
| Quick Ratio (Most Recent Fiscal Quarter) |
1.24 |
| Debt to Common Equity (Most Recent Fiscal Quarter) |
0.51 |
| Inventory Turnover (Trailing 12 Months) |
3.01 |
| Book Value per Share (Most Recent Fiscal Quarter) |
$22.60 |
| Earnings per Share (Most Recent Fiscal Quarter) |
$2.20 |
| Earnings per Share (Most Recent Fiscal Year) |
$8.68 |
| Diluted Earnings per Share (Trailing 12 Months) |
$6.36 |